Ketogenic diets as an adjuvant cancer therapy: History and potential mechanism

Redox Biology

Volumn 2, Issue 1, 2014, Pages 963-970

  Allen, Bryan G ^a   Bhatia, Sudershan K ^a   Anderson, Carryn M ^a   Eichenberger Gilmore, Julie M ^a   Sibenaller, Zita A ^a   Mapuskar, Kranti A ^a   Schoenfeld, Joshua D ^a   Buatti, John M ^a   Spitz, Douglas R ^a   Fath, Melissa A ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Cancer therapy; Ketogenic diet; Oxidative stress

Indexed keywords

CARBOHYDRATE; FAT; GLUCOSE; HYDROGEN PEROXIDE; HYDROPEROXIDE; OXYGEN; REACTIVE OXYGEN METABOLITE; SUPEROXIDE;

AEROBIC METABOLISM; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL METABOLISM; GLUCOSE METABOLISM; HUMAN; KETOGENIC DIET; METABOLIC STRESS; MITOCHONDRIAL RESPIRATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; ADJUVANT CHEMORADIOTHERAPY; ANIMAL; METABOLISM; MITOCHONDRION; NEOPLASM; PROCEDURES; CANCER CONTROL; CLINICAL EFFECTIVENESS; COLON ADENOCARCINOMA; COLON CANCER; GLIOBLASTOMA; GLYCOLYSIS; LIPID DIET; LOW CARBOHYDRATE DIET; NON SMALL CELL LUNG CANCER; PROTEIN RESTRICTION; RISK FACTOR; TREATMENT INDICATION;

ANIMALS; CHEMORADIOTHERAPY, ADJUVANT; DIET, KETOGENIC; GLUCOSE; HUMANS; HYDROGEN PEROXIDE; MITOCHONDRIA; NEOPLASMS; SUPEROXIDES;

EID: 84908574610     PISSN: 22132317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.redox.2014.08.002     Document Type: Review

References (79)

1. Warburg O. On the origin of cancer cells. Science 1956, 123(3191):309-314. http://www.ncbi.nlm.nih.gov/pubmed/13298683, 10.1016/j.redox.2014.08.002.
2. Ahmad I.M., Aykin-Burns N., Sim J.E., Walsh S.A., Higashikubo R., Buettner G.R., Venkataraman S., Mackey M.A., Flanagan S.W., Oberley L.W., Spitz D.R. Mitochondrial O2·- and H2O2 mediate glucose deprivation-induced stress in human cancer cells. Journal of Biological Chemistry 2005, 280(6):4254-4263. http://www.ncbi.nlm.nih.gov/pubmed/15561720, 10.1016/j.redox.2014.08.002.
3. Aykin-Burns N., Ahmad I.M., Zhu Y., Oberley L.W., Spitz D.R. Increased levels of superoxide and H2O2 mediate the differential susceptibility of cancer cells versus normal cells to glucose deprivation. Biochemical Journal 2009, 418(1):29-37. http://www.ncbi.nlm.nih.gov/pubmed/18937644, 10.1016/j.redox.2014.08.002.
4. Spitz D.R., Sim J.E., Ridnour L.A., Galoforo S.S., Lee Y.J. Glucose deprivation-induced oxidative stress in human tumor cells. A fundamental defect in metabolism?. Annals of the New York Academy of Sciences 2000, 899:349-362. http://www.ncbi.nlm.nih.gov/pubmed/10863552.
5. Allen B.G., Bhatia S.K., Buatti J.M., Brandt K.E., Lindholm K.E., Button A.M., Szweda L.I., Smith B.J., Spitz D.R., Fath M.A. Ketogenic diets enhance oxidative stress and radio-chemo-therapy responses in lung cancer xenografts. Clinical Cancer Research: 2013, 19(14):3905-3913. http://www.ncbi.nlm.nih.gov/pubmed/23743570, 10.1016/j.redox.2014.08.002.
6. Bize I.B., Oberley L.W., Morris H.P. Superoxide dismutase and superoxide radical in Morris hepatomas. Cancer Research 1980, 40(10):3686-3693. http://www.ncbi.nlm.nih.gov/pubmed/6254638.
7. Coleman M.C., Asbury C.R., Daniels D., Du J., Aykin-Burns N., Smith B.J., Li L., Spitz D.R., Cullen J.J. 2-deoxy-d-glucose causes cytotoxicity, oxidative stress, and radiosensitization in pancreatic cancer. Free Radical Biology & Medicine 2008, 44(3):322-331. http://www.ncbi.nlm.nih.gov/pubmed/18215740, 10.1016/j.redox.2014.08.002.
8. Dixon S.J., Stockwell B.R. The role of iron and reactive oxygen species in cell death. Nature Chemical Biology 2013, 10(1):9-17.
9. Fath M.A., Ahmad I.M., Smith C.J., Spence J., Spitz D.R. Enhancement of carboplatin-mediated lung cancer cell killing by simultaneous disruption of glutathione and thioredoxin metabolism. Clinical Cancer Research: 2011, 17(19):6206-6217. http://www.ncbi.nlm.nih.gov/pubmed/21844013, 10.1016/j.redox.2014.08.002.
10. Fath M.A., Diers A.R., Aykin-Burns N., Simons A.L., Hua L., Spitz D.R. Mitochondrial electron transport chain blockers enhance 2-deoxy-d-glucose induced oxidative stress and cell killing in human colon carcinoma cells. Cancer Biology & Therapy 2009, 8(13):1228-1236. http://www.ncbi.nlm.nih.gov/pubmed/19411865, 10.1016/j.redox.2014.08.002.
11. Hadzic T., Aykin-Burns N., Zhu Y., Coleman M.C., Leick K., Jacobson G.M., Spitz D.R. Paclitaxel combined with inhibitors of glucose and hydroperoxide metabolism enhances breast cancer cell killing via H2O2-mediated oxidative stress. Free Radical Biology & Medicine 2010, 48(8):1024-1033. http://www.ncbi.nlm.nih.gov/pubmed/20083194, 10.1016/j.redox.2014.08.002.
12. Ishikawa K., Takenaga K., Akimoto M., Koshikawa N., Yamaguchi A., Imanishi H., Nakada K., Honma Y., Hayashi J. ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis. Science 2008, 320(5876):661-664. http://www.ncbi.nlm.nih.gov/pubmed/18388260, 10.1016/j.redox.2014.08.002.
13. Oberley L.W. Anticancer therapy by overexpression of superoxide dismutase. Antioxidants & Redox Signaling 2001, 3(3):461-472. http://www.ncbi.nlm.nih.gov/pubmed/11491657, 10.1016/j.redox.2014.08.002.
14. Oberley L.W. Mechanism of the tumor suppressive effect of MnSOD overexpression. Biomedicine & Pharmacotherapy 2005, 59(4):143-148. http://www.ncbi.nlm.nih.gov/pubmed/15862707, 10.1016/j.redox.2014.08.002.
15. Springer E.L. Comparative study of the cytoplasmic organelles of epithelial cell lines derived from human carcinomas and nonmalignant tissues. Cancer Research 1980, 40(3):803-817. http://www.ncbi.nlm.nih.gov/pubmed/7193514.
16. Wen S., Zhu D., Huang P. Targeting cancer cell mitochondria as a therapeutic approach. Future Medicinal Chemistry 2013, 5(1):53-67.
17. Wondrak G.T. Redox-directed cancer therapeutics: molecular mechanisms and opportunities. Antioxidants & Redox Signaling 2009, 11(12):3013-3069. http://www.ncbi.nlm.nih.gov/pubmed/19496700, 10.1016/j.redox.2014.08.002.
18. Westman E.C., Yancy W.S., Mavropoulos J.C., Marquart M., McDuffie J.R. The effect of a low-carbohydrate, ketogenic diet versus a low-glycemic index diet on glycemic control in type 2 diabetes mellitus. Nutrition & Metabolism 2008, 5:36. http://www.ncbi.nlm.nih.gov/pubmed/19099589, 10.1016/j.redox.2014.08.002.
19. Valayannopoulos V., Bajolle F., Arnoux J.B., Dubois S., Sannier N., Baussan C., Petit F., Labrune P., Rabier D., Ottolenghi C., Vassault A., Broissand C., Bonnet D., de Lonlay P. Successful treatment of severe cardiomyopathy in glycogen storage disease type III with D,l-3-hydroxybutyrate, ketogenic and high-protein diet. Pediatric Research 2011, 70(6):638-641. http://www.ncbi.nlm.nih.gov/pubmed/21857385, 10.1016/j.redox.2014.08.002.
20. Gilbert D.L., Pyzik P.L., Freeman J.M. The ketogenic diet: seizure control correlates better with serum beta-hydroxybutyrate than with urine ketones. Journal of Child Neurology 2000, 15(12):787-790. http://www.ncbi.nlm.nih.gov/pubmed/11198492, 10.1016/j.redox.2014.08.002.
21. Wheless J.W. History and origin of the ketogenic diet. Epilepsy and the Ketogenic Diet 2004, 31-50. Humana Press, Totowa, NJ. C.E. Stafstrom, J.M. Rho (Eds.).
22. Neal E.G., Chaffe H., Schwartz R.H., Lawson M.S., Edwards N., Fitzsimmons G., Whitney A., Cross J.H. The ketogenic diet for the treatment of childhood epilepsy: a randomised controlled trial. Lancet Neurology 2008, 7(6):500-506. http://www.ncbi.nlm.nih.gov/pubmed/18456557, 10.1016/j.redox.2014.08.002.
23. Lambrechts D.A., Bovens M.J., de la Parra N.M., Hendriksen J.G., Aldenkamp A.P., Majoie M.J. Ketogenic diet effects on cognition, mood, and psychosocial adjustment in children. Acta Neurologica Scandinavica 2013, 127(2):103-108. http://www.ncbi.nlm.nih.gov/pubmed/22690843, 10.1016/j.redox.2014.08.002.
24. Klepper J., Diefenbach S., Kohlschütter A., Voit T. Effects of the ketogenic diet in the glucose transporter 1 deficiency syndrome. Prostaglandins, Leukotrienes, and Essential Fatty Acids 2004, 70(3):321-327. http://www.ncbi.nlm.nih.gov/pubmed/14769490, 10.1016/j.redox.2014.08.002.
25. Zhao Z., Lange D.J., Voustianiouk A., MacGrogan D., Ho L., Suh J., Humala N., Thiyagarajan M., Wang J., Pasinetti G.M. A ketogenic diet as a potential novel therapeutic intervention in amyotrophic lateral sclerosis. BMC Neuroscience 2006, 7:29. http://www.ncbi.nlm.nih.gov/pubmed/16584562, 10.1016/j.redox.2014.08.002.
26. Barañano K.W., Hartman A.L. The ketogenic diet: uses in epilepsy and other neurologic illnesses. Current Treatment Options in Neurology 2008, 10(6):410-419. http://www.ncbi.nlm.nih.gov/pubmed/18990309, 10.1016/j.redox.2014.08.002.
27. Evangeliou A., Vlachonikolis I., Mihailidou H., Spilioti M., Skarpalezou A., Makaronas N., Prokopiou A., Christodoulou P., Liapi-Adamidou G., Helidonis E., Sbyrakis S., Smeitink J. Application of a ketogenic diet in children with autistic behavior: pilot study. Journal of Child Neurology 2003, 18(2):113-118. http://www.ncbi.nlm.nih.gov/pubmed/12693778, 10.1016/j.redox.2014.08.002.
28. Murphy P., Likhodii S., Nylen K., Burnham W.M. The antidepressant properties of the ketogenic diet. Biological Psychiatry 2004, 56(12):981-983. http://www.ncbi.nlm.nih.gov/pubmed/15601609, 10.1016/j.redox.2014.08.002.
29. Mavropoulos J.C., Yancy W.S., Hepburn J., Westman E.C. The effects of a low-carbohydrate, ketogenic diet on the polycystic ovary syndrome: a pilot study. Nutrition & Metabolism 2005, 2:35. http://www.ncbi.nlm.nih.gov/pubmed/16359551, 10.1016/j.redox.2014.08.002.
30. Tisdale M.J., Brennan R.A., Fearon K.C. Reduction of weight loss and tumour size in a cachexia model by a high fat diet. British Journal of Cancer 1987, 56(1):39-43. http://www.ncbi.nlm.nih.gov/pubmed/3620317, 10.1016/j.redox.2014.08.002.
31. Maurer G.D., Brucker D.P., Bähr O., Harter P.N., Hattingen E., Walenta S., Mueller-Klieser W., Steinbach J.P., Rieger J. Differential utilization of ketone bodies by neurons and glioma cell lines: a rationale for ketogenic diet as experimental glioma therapy. BMC Cancer 2011, 11:315. http://www.ncbi.nlm.nih.gov/pubmed/21791085, 10.1016/j.redox.2014.08.002.
32. Seyfried T.N., Sanderson T.M., El-Abbadi M.M., McGowan R., Mukherjee P. Role of glucose and ketone bodies in the metabolic control of experimental brain cancer. British Journal of Cancer 2003, 89(7):1375-1382. http://www.ncbi.nlm.nih.gov/pubmed/14520474, 10.1016/j.redox.2014.08.002.
33. Stafford P., Abdelwahab M.G., Kim Y., Preul M.C., Rho J.M., Scheck A.C. The ketogenic diet reverses gene expression patterns and reduces reactive oxygen species levels when used as an adjuvant therapy for glioma. Nutrition & Metabolism 2010, 7:74. http://www.ncbi.nlm.nih.gov/pubmed/20831808, 10.1016/j.redox.2014.08.002.
34. Beck S.A., Tisdale M.J. Nitrogen excretion in cancer cachexia and its modification by a high fat diet in mice. Cancer Research 1989, 49(14):3800-3804. http://www.ncbi.nlm.nih.gov/pubmed/2736521.
35. Otto C., Kaemmerer U., Illert B., Muehling B., Pfetzer N., Wittig R., Voelker H.U., Thiede A., Coy J.F. Growth of human gastric cancer cells in nude mice is delayed by a ketogenic diet supplemented with omega-3 fatty acids and medium-chain triglycerides. BMC Cancer 2008, 8:122. http://www.ncbi.nlm.nih.gov/pubmed/18447912, 10.1016/j.redox.2014.08.002.
36. Freedland S.J., Mavropoulos J., Wang A., Darshan M., Demark-Wahnefried W., Aronson W.J., Cohen P., Hwang D., Peterson B., Fields T., Pizzo S.V., Isaacs W.B. Carbohydrate restriction, prostate cancer growth, and the insulin-like growth factor axis. Prostate 2008, 68(1):11-19. http://www.ncbi.nlm.nih.gov/pubmed/17999389, 10.1016/j.redox.2014.08.002.
37. Masko E.M., Thomas J.A., Antonelli J.A., Lloyd J.C., Phillips T.E., Poulton S.H., Dewhirst M.W., Pizzo S.V., Freedland S.J. Low-carbohydrate diets and prostate cancer: How low is "low enough"?. Cancer Prevention Research 2010, 3(9):1124-1131. 10.1016/j.redox.2014.08.002.
38. Mavropoulos J.C., Buschemeyer W.C., Tewari A.K., Rokhfeld D., Pollak M., Zhao Y., Febbo P.G., Cohen P., Hwang D., Devi G., Demark-Wahnefried W., Westman E.C., Peterson B.L., Pizzo S.V., Freedland S.J. The effects of varying dietary carbohydrate and fat content on survival in a murine LNCaP prostate cancer xenograft model. Cancer Prevention Research 2009, 2(6):557-565. 10.1016/j.redox.2014.08.002.
39. Abdelwahab M.G., Fenton K.E., Preul M.C., Rho J.M., Lynch A., Stafford P., Scheck A.C. The ketogenic diet is an effective adjuvant to radiation therapy for the treatment of malignant glioma. PloS One 2012, 7(5):e36197. http://www.ncbi.nlm.nih.gov/pubmed/22563484, 10.1016/j.redox.2014.08.002.
40. Lee C., Raffaghello L., Brandhorst S., Safdie F.M., Bianchi G., Martin-Montalvo A., Pistoia V., Wei M., Hwang S., Merlino A., Emionite L., de Cabo R., Longo V.D. Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy. Science Translational Medicine 2012, 4(124). http://www.ncbi.nlm.nih.gov/pubmed/22323820, 10.1016/j.redox.2014.08.002.
41. Safdie F.M., Dorff T., Quinn D., Fontana L., Wei M., Lee C., Cohen P., Longo V.D. Fasting and cancer treatment in humans: a case series report. Aging 2009, 1(12):988-1007. http://www.ncbi.nlm.nih.gov/pubmed/20157582.
42. Nebeling L.C., Miraldi F., Shurin S.B., Lerner E. Effects of a ketogenic diet on tumor metabolism and nutritional status in pediatric oncology patients: two case reports. Journal of the American College of Nutrition 1995, 14(2):202-208. http://www.ncbi.nlm.nih.gov/pubmed/7790697, 10.1016/j.redox.2014.08.002.
43. Zuccoli G., Marcello N., Pisanello A., Servadei F., Vaccaro S., Mukherjee P., Seyfried T.N. Metabolic management of glioblastoma multiforme using standard therapy together with a restricted ketogenic diet: case report. Nutrition & Metabolism 2010, 7:33. 10.1016/j.redox.2014.08.002.
44. Schmidt M., Pfetzer N., Schwab M., Strauss I., Kämmerer U. Effects of a ketogenic diet on the quality of life in 16 patients with advanced cancer: a pilot trial. Nutrition & Metabolism 2011, 8(1):54. http://www.ncbi.nlm.nih.gov/pubmed/21794124, 10.1016/j.redox.2014.08.002.
45. Kroemer G., Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 2008, 13(6):472-482. http://www.ncbi.nlm.nih.gov/pubmed/18538731, 10.1016/j.redox.2014.08.002.
46. Attardi G., Schatz G. Biogenesis of mitochondria. Annual Review of Cell. Biology 1988, 4:289-333. 10.1016/j.redox.2014.08.002.
47. Carew J.S., Huang P. Mitochondrial defects in cancer. Molecular Cancer 2002, 1:9. http://www.ncbi.nlm.nih.gov/pubmed/12513701, 10.1016/j.redox.2014.08.002.
48. Fliss M.S., Usadel H., Caballero O.L., Wu L., Buta M.R., Eleff S.M., Jen J., Sidransky D. Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. Science 2000, 287(5460):2017-2019. http://www.ncbi.nlm.nih.gov/pubmed/10720328, 10.1016/j.redox.2014.08.002.
49. Polyak K., Li Y., Zhu H., Lengauer C., Willson J.K., Markowitz S.D., Trush M.A., Kinzler K.W., Vogelstein B. Somatic mutations of the mitochondrial genome in human colorectal tumours. Nature Genetics 1998, 20(3):291-293. http://www.ncbi.nlm.nih.gov/pubmed/9806551, 10.1016/j.redox.2014.08.002.
50. Zhou S., Kachhap S., Sun W., Wu G., Chuang A., Poeta L., Grumbine L., Mithani S.K., Chatterjee A., Koch W., Westra W.H., Maitra A., Glazer C., Carducci M., Sidransky D., McFate T., Verma A., Califano J.A. Frequency and phenotypic implications of mitochondrial DNA mutations in human squamous cell cancers of the head and neck. Proceedings of the National Academy of Sciences of the United States of America 2007, 104(18):7540-7545. http://www.ncbi.nlm.nih.gov/pubmed/17456604, 10.1016/j.redox.2014.08.002.
51. Petros J.A., Baumann A.K., Ruiz-Pesini E., Amin M.B., Sun C.Q., Hall J., Lim S., Issa M.M., Flanders W.D., Hosseini S.H., Marshall F.F., Wallace D.C. mtDNA mutations increase tumorigenicity in prostate cancer. Proceedings of the National Academy of Sciences of the United States of America 2005, 102(3):719-724. http://www.ncbi.nlm.nih.gov/pubmed/15647368, 10.1016/j.redox.2014.08.002.
52. Liu V.W., Shi H.H., Cheung A.N., Chiu P.M., Leung T.W., Nagley P., Wong L.C., Ngan H.Y. High incidence of somatic mitochondrial DNA mutations in human ovarian carcinomas. Cancer Research 2001, 61(16):5998-6001. http://www.ncbi.nlm.nih.gov/pubmed/11507041.
53. Nishikawa M., Nishiguchi S., Shiomi S., Tamori A., Koh N., Takeda T., Kubo S., Hirohashi K., Kinoshita H., Sato E., Inoue M. Somatic mutation of mitochondrial DNA in cancerous and noncancerous liver tissue in individuals with hepatocellular carcinoma. Cancer Research 2001, 61(5):1843-1845. http://www.ncbi.nlm.nih.gov/pubmed/11280735.
54. Esposito L.A., Melov S., Panov A., Cottrell B.A., Wallace D.C. Mitochondrial disease in mouse results in increased oxidative stress. Proceedings of the National Academy of Sciences of the United States of America 1999, 96(9):4820-4825. http://www.ncbi.nlm.nih.gov/pubmed/10220377, 10.1016/j.redox.2014.08.002.
55. Szatrowski T.P., Nathan C.F. Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Research 1991, 51(3):794-798. http://www.ncbi.nlm.nih.gov/pubmed/1846317.
56. Brandon M., Baldi P., Wallace D.C. Mitochondrial mutations in cancer. Oncogene 2006, 25(34):4647-4662. http://www.ncbi.nlm.nih.gov/pubmed/16892079, 10.1016/j.redox.2014.08.002.
57. Wallace D.C., Fan W. The pathophysiology of mitochondrial disease as modeled in the mouse. Genes & Development 2009, 23(15):1714-1736. http://www.ncbi.nlm.nih.gov/pubmed/19651984, 10.1016/j.redox.2014.08.002.
58. Rigo P., Paulus P., Kaschten B.J., Hustinx R., Bury T., Jerusalem G., Benoit T., Foidart-Willems J. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. European Journal of Nuclear Medicine 1996, 23(12):1641-1674. http://www.ncbi.nlm.nih.gov/pubmed/8929320, 10.1016/j.redox.2014.08.002.
59. Boros L.G., Lee P.W., Brandes J.L., Cascante M., Muscarella P., Schirmer W.J., Melvin W.S., Ellison E.C. Nonoxidative pentose phosphate pathways and their direct role in ribose synthesis in tumors: Is cancer a disease of cellular glucose metabolism?. Medical Hypotheses 1998, 50(1):55-59. http://www.ncbi.nlm.nih.gov/pubmed/9488183, 10.1016/j.redox.2014.08.002.
60. Buettner G.R. Superoxide dismutase in redox biology: the roles of superoxide and hydrogen peroxide. Anti-Cancer Agents in Medicinal Chemistry 2011, 11(4):341-346. http://www.ncbi.nlm.nih.gov/pubmed/21453242, 10.1016/j.redox.2014.08.002.
61. Geschwind J.F., Ko Y.H., Torbenson M.S., Magee C., Pedersen P.L. Novel therapy for liver cancer: direct intraarterial injection of a potent inhibitor of ATP production. Cancer Research 2002, 62(14):3909-3913. http://www.ncbi.nlm.nih.gov/pubmed/12124317.
62. Le A., Cooper C.R., Gouw A.M., Dinavahi R., Maitra A., Deck L.M., Royer R.E., Vander Jagt D.L., Semenza G.L., Dang C.V. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proceedings of the National Academy of Sciences of the United States of America 2010, 107(5):2037-2042. http://www.ncbi.nlm.nih.gov/pubmed/20133848, 10.1016/j.redox.2014.08.002.
63. Lin X., Zhang F., Bradbury C.M., Kaushal A., Li L., Spitz D.R., Aft R.L., Gius D. 2-Deoxy-d-glucose-induced cytotoxicity and radiosensitization in tumor cells is mediated via disruptions in thiol metabolism. Cancer Research 2003, 63(12):3413-3417. http://www.ncbi.nlm.nih.gov/pubmed/12810678.
64. Simons A.L., Ahmad I.M., Mattson D.M., Dornfeld K.J., Spitz D.R. 2-deoxy-d-glucose combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells. Cancer Research 2007, 67(7):3364-3370. http://www.ncbi.nlm.nih.gov/pubmed/17409446, 10.1016/j.redox.2014.08.002.
65. Trachootham D., Alexandre J., Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?. Nature Reviews. Drug Discovery 2009, 8(7):579-591. http://www.ncbi.nlm.nih.gov/pubmed/19478820, 10.1016/j.redox.2014.08.002.
66. Jain S.K., Kannan K., Lim G. Ketosis (acetoacetate) can generate oxygen radicals and cause increased lipid peroxidation and growth inhibition in human endothelial cells. Free Radical Biology & Medicine 1998, 25(9):1083-1088. http://www.ncbi.nlm.nih.gov/pubmed/9870562, 10.1016/j.redox.2014.08.002.
67. Abdelmegeed M.A., Kim S.K., Woodcroft K.J., Novak R.F. Acetoacetate activation of extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase in primary cultured rat hepatocytes: role of oxidative stress. Journal of Pharmacology and Experimental Therapeutics 2004, 310(2):728-736. http://www.ncbi.nlm.nih.gov/pubmed/15051799, 10.1016/j.redox.2014.08.002.
68. Pelletier A., Coderre L. Ketone bodies alter dinitrophenol-induced glucose uptake through AMPK inhibition and oxidative stress generation in adult cardiomyocytes. American Journal of Physiology: Endocrinology and Metabolism 2007, 292(5):E1325-E1332. http://www.ncbi.nlm.nih.gov/pubmed/17227964, 10.1016/j.redox.2014.08.002.
69. Poff A.M., Ari C., Seyfried T.N., D'Agostino D.P. The ketogenic diet and hyperbaric oxygen therapy prolong survival in mice with systemic metastatic cancer. PloS One 2013, 8(6):e65522. http://www.ncbi.nlm.nih.gov/pubmed/23755243, 10.1016/j.redox.2014.08.002.
70. Dhamija R., Eckert S., Wirrell E. Ketogenic diet. Canadian Journal of Neurological Sciences 2013, 40(2):158-167. http://www.ncbi.nlm.nih.gov/pubmed/23419562.
71. Nangia S., Caraballo R.H., Kang H.C., Nordli D.R., Scheffer I.E. Is the ketogenic diet effective in specific epilepsy syndromes?. Epilepsy Research 2012, 100(3):252-257. http://www.ncbi.nlm.nih.gov/pubmed/22424762, 10.1016/j.redox.2014.08.002.
72. Mosek A., Natour H., Neufeld M.Y., Shiff Y., Vaisman N. Ketogenic diet treatment in adults with refractory epilepsy: a prospective pilot study. Seizure: The Journal of the British Epilepsy Association 2009, 18(1):30-33. http://www.ncbi.nlm.nih.gov/pubmed/18675556, 10.1016/j.redox.2014.08.002.
73. Hayashi A., Kumada T., Nozaki F., Hiejima I., Miyajima T., Fujii T. Changes in serum levels of selenium, zinc and copper in patients on a ketogenic diet using Keton formula. No to Hattatsu. Brain and Development 2013, 45(4):288-293. http://www.ncbi.nlm.nih.gov/pubmed/23951940.
74. Westerterp-Plantenga M.S., Nieuwenhuizen A., Tomé D., Soenen S., Westerterp K.R. Dietary protein, weight loss, and weight maintenance. Annual Review of Nutrition 2009, 29:21-41. http://www.ncbi.nlm.nih.gov/pubmed/19400750, 10.1016/j.redox.2014.08.002.
75. McNally M.A., Pyzik P.L., Rubenstein J.E., Hamdy R.F., Kossoff E.H. Empiric use of potassium citrate reduces kidney-stone incidence with the ketogenic diet. Pediatrics 2009, 124(2):e300-e304. http://www.ncbi.nlm.nih.gov/pubmed/19596731, 10.1016/j.redox.2014.08.002.
76. Sampath A., Kossoff E.H., Furth S.L., Pyzik P.L., Vining E.P. Kidney stones and the ketogenic diet: risk factors and prevention. Journal of Child Neurology 2007, 22(4):375-378. http://www.ncbi.nlm.nih.gov/pubmed/17621514, 10.1016/j.redox.2014.08.002.
77. Bergqvist A.G., Schall J.I., Stallings V.A., Zemel B.S. Progressive bone mineral content loss in children with intractable epilepsy treated with the ketogenic diet. American Journal of Clinical Nutrition 2008, 88(6):1678-1684. http://www.ncbi.nlm.nih.gov/pubmed/19064531, 10.1016/j.redox.2014.08.002.
78. Yancy W.S., Olsen M.K., Guyton J.R., Bakst R.P., Westman E.C. A low-carbohydrate, ketogenic diet versus a low-fat diet to treat obesity and hyperlipidemia: a randomized, controlled trial. Annals of Internal Medicine 2004, 140(10):769-777. http://www.ncbi.nlm.nih.gov/pubmed/15148063, 10.1016/j.redox.2014.08.002.
79. Yancy W.S., Westman E.C., McDuffie J.R., Grambow S.C., Jeffreys A.S., Bolton J., Chalecki A., Oddone E.Z. A randomized trial of a low-carbohydrate diet vs orlistat plus a low-fat diet for weight loss. Archives of Internal Medicine 2010, 170(2):136-145. http://www.ncbi.nlm.nih.gov/pubmed/20101008, 10.1016/j.redox.2014.08.002.